ZENTALIS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.16 USD | -0.95% |
|
-20.76% | -72.54% |
| 06-20 | UBS Downgrades Zentalis Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $5 From $28 | MT |
| 06-18 | US Equity Markets Close Up Tuesday Following Less-Than-Expected Retail Sales Growth | MT |
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Companyâs lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
4.2
USD
Average target price
10.7
USD
Spread / Average Target
+154.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -72.54% | 298M | |
| +16.49% | 122B | |
| +21.73% | 116B | |
| +22.18% | 27.03B | |
| -21.81% | 20.36B | |
| -16.89% | 16.43B | |
| -18.81% | 15.91B | |
| -44.74% | 15.6B | |
| +62.72% | 14.94B | |
| +3.09% | 13.59B |
- Stock Market
- Equities
- ZNTL Stock
- News Zentalis Pharmaceuticals, Inc.
- Sector Update: Health Care Stocks Edge Up Late Afternoon
